CERo Therapeutics Holdings, Inc. has announced that TriStar Centennial Medical Center in Nashville, Tennessee, will serve as a clinical trial site for its Phase 1 clinical study of CER-1236, a new ...

SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next ...

In other recent news, CERo Therapeutics Holdings, Inc. has completed the first cohort of its Phase 1 clinical trial for its CER-1236 therapy targeting acute myeloid leukemia, with no dose-limiting ...

CERO Therapeutics announces first patient dosed in Phase 1 trial of CER-1236 for acute myeloid leukemia, with upcoming ASCO presentation. CERo Therapeutics Holdings, Inc. has announced the initial ...

CERo Therapeutics (NASDAQ:CERO) will implement a 1-for-20 reverse stock split on June 13, 2025. The split reduces outstanding common shares from ~10.32M to ~516,092. The stock will begin trading on a ...

Company to host analyst call at 5:00pm ET today to discuss progress to date and expansion of clinical trial SOUTH SAN FRANCISCO, Calif, Jan. 07, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, ...

CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is ...

Cero Therapeutics Holdings, Inc. (NASDAQ:CERO), a biotech firm specializing in biological products, is confronting the possibility of delisting from The Nasdaq Global Market due to non-compliance with ...

CER‑T therapy shows initial safety signals and prompts protocol expansion CERo has released new findings from its ongoing phase 1 CertainT‑1 study evaluating CER‑1236, a first‑in‑human chimeric ...

CERo Therapeutics (CERO) announced that its board of directors has determined to effect a one-for-twenty reverse stock split of the Company’s common stock, par value $0.0001 per share. The reverse ...